Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Equities research analysts at Wedbush dropped their Q1 2025 earnings estimates for Astria Therapeutics in a research report issued on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.40). Wedbush has a “Outperform” rating and a $28.00 price target on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at $2.40 EPS.

ATXS has been the subject of a number of other reports. JMP Securities assumed coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Finally, Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics has a consensus rating of “Buy” and an average target price of $26.67.

Astria Therapeutics Price Performance

Shares of ATXS opened at $6.45 on Friday. Astria Therapeutics has a 1-year low of $5.73 and a 1-year high of $16.90. The stock has a market cap of $364.00 million, a PE ratio of -3.09 and a beta of 0.69. The firm has a 50-day simple moving average of $7.19 and a two-hundred day simple moving average of $9.57.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC boosted its stake in shares of Astria Therapeutics by 29.2% in the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares during the period. RA Capital Management L.P. boosted its stake in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after purchasing an additional 61,457 shares during the period. Vestal Point Capital LP boosted its stake in shares of Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after purchasing an additional 180,000 shares during the period. Fcpm Iii Services B.V. purchased a new position in shares of Astria Therapeutics in the fourth quarter valued at approximately $25,680,000. Finally, Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock valued at $23,936,000 after purchasing an additional 41,833 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.